Author presents a long thesis on KORU Medical Systems (KRMD), citing Medicare's shift to at-home care, new biologic pump clearances, and solid micro-cap med-tech fundamentals.
KRMD — LONG Author is long KRMD, a micro-cap med-tech whose mechanical infusion pumps dominate subcutaneous immunoglobulin therapy and are expanding into new biologic indications. The core claim is that Medicare's push toward at-home care creates a tailwind for KRMD because its pumps make at-home treatment safer and cheaper; stated catalysts include FDA 510(k) clearance for RYSTIGGO and a submitted 510(k) for Phesgo in HER2-positive breast cancer. Author cites 22% 2025 revenue growth, 61-63% gross margins, positive operating cash flow, ~6x P/S and expects positive EPS by 2026/2027. Valuation is noted as not 'bargain bin,' the closest stated risk.
Hello all, I want to bring KRMD (KORU Medical Systems) to the table. I found this company in January and have been slowly building a position. (This isn't value per say, more garp-but I hope you like it)
The Thesis: My view is that Medicare is aggressively moving toward "at-home" care to slash hospital costs. Any company that makes at-home treatment safer and cheaper for the government is sitting in a tailwind. I believe KRMD fits that bill perfectly.